APM - Aptorum shares jump as Canada approves early-stage infection drug trial

Small-cap Aptorum (APM) soars 65% in premarket after Health Canada signs off its trial application to commence a Phase 1 study of the company's lead candidate, ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.The planned Phase 1 trial is targeted to recruit up to 48 and 24 healthy volunteers for the single-ascending dose and multiple- ascending dose cohorts, respectively. The primary objective of the trial is to evaluate the safety and tolerability of ALS-4, with secondary objective is to assess the pharmacokinetic profile.

For further details see:

Aptorum shares jump as Canada approves early-stage infection drug trial